HCC组织CDC20表达及其与发病机制的关系研究*

doi:10.3969/j.issn.1672-5069.2023.01.025

摘要/Abstract

摘要： 目的肝细胞癌(HCC)是世界上最常见的肝恶性肿瘤之一。HCC的病因和潜在的分子事件尚不清楚。我们应用综合生物信息学技术识别与HCC相关的关键致病基因细胞分裂周期20(CDC20),并揭示其潜在的分子机制。方法从Gene Expression Omnibus (GEO)数据库下载GSE36376基因表达谱,共433个样本,其中HCC组织240例,正常肝组织193例,用综合生物信息学方法进行深入分析。应用RStudio中的R软件筛选HCC和正常肝组织差异表达基因(DEG),从STRING数据库中构建DEG的蛋白质-蛋白质相互作用(PPI)网络,应用Metascape在线工具进行富集分析,采用MCODE法对Hub基因进行鉴定。结果筛选GSE36376数据集得到706个DEG,其中共鉴定出554个下调基因和152个上调基因;从PPI网络中鉴定出DEG关系基因,显著上调基因是UBE2C、CDC20、COL4A1、NUSAP1、HSP90AB1和CDKN3;Metascape富集分析表明,在GO生物过程中,主要集中在小分子分解代谢过程、一元羧酸代谢过程、类固醇代谢过程、辅因子代谢过程、药物分解代谢过程、初级酒精代谢过程、对有毒物质的反应、有机阴离子转运、单糖代谢过程、芳香族氨基酸家族代谢过程、解毒作用、伯醇分解代谢过程和有机环状化合物分解代谢过程等;在KEGG 信号通路中,主要集中在碳代谢、脂肪酸降解、补体和凝血级联、色氨酸代谢和过氧物酶体等过程;MCODE分析显示Hub基因是UBE2C、CDC20和HSP90AB1。结论应用综合生物信息学方法筛选出的CDC20基因是HCC发生发展的关键基因,对HCC的早期诊断和预防具有临床意义,为HCC的防治提供了有效的靶点。

关键词: 肝细胞癌, 细胞分裂周期20, GEO数据, 差异表达基因

Abstract: Objective Hepatocellular carcinoma (HCC) is one of the most common liver malignancies in the world. The etiology and molecular events HCC are still unclear. We tried to identify the key pathogenic gene, the cell division cycle 20 (CDC20) by comprehensive bioinformatics, which was related to the pathogenesis of HCC with certain underlying molecular mechanism. Methods We downloaded GSE36376 gene expression profile from Gene Expression Omnibus (GEO) database, found 433 samples, of which 240 HCC tissues and 193 of normal liver tissues, and were analyzed by comprehensive bioinformatics. The R software in RStudio was applied to screen the differential gene expression (DEG) in HCC and normal liver tissues, and the protein-protein interaction (PPI) network of DEG was constructed from the STRING database. The Metascape online tool was applied to carry out enrichment analysis, at the same time, the MCODE was used to identify Hub gene. Results The GSE36376 data was screened to get 706 DEGs, among them, a total of 554 down-regulated genes and 152 up-regulated genes were identified; the significant up-regulated genes were UBE2C, CDC20, COL4A1, NUSAP1, HSP90AB1, and CDKN3 from the PPI network; the Metascape enrichment analysis showed that in the GO biological process, it was mainly concentrated in the small molecule catabolism, the monocarboxylic acid metabolism, the steroid metabolism, the cofactor metabolism, the drug catabolism, the primary alcohol metabolism, and the effects of toxic substances; it also involved the organic anion transport, monosaccharide metabolism, aromatic amino acid family metabolism, detoxification, primary alcohol catabolism, and organic cyclic compound catabolism, etc; as for the KEGG signal pathway, it was mainly focused on carbon metabolism, fatty acid degradation, complement and coagulation cascade, tryptophan metabolism and peroxisomes, etc; the Hub genes were UBE2C, CDC20 and HSP90AB1 from MCODE. Conclusion The CDC20 gene obtained by comprehensive bioinformatics is a key gene for pathogenesis of HCC, which might be important for early diagnosis and therapeutic target.

Key words: Hepatocellular carcinoma, Cell division cycle 20, GEO database, Differential gene expression

邹春燕, 何焰鹏, 柴秀坤, 谢长顺, 李莉, 付丽坤. HCC组织CDC20表达及其与发病机制的关系研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 95-99.

Zou Chunyan, He Yanpeng, Chai Xiukun, et al. Pathogenesis of hepatocellular carcinoma associated with CDC20 expression[J]. Journal of Practical Hepatology, 2023, 26(1): 95-99.

参考文献

[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics.CA Cancer J Clin,2011,61: 69-90.
[2] El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology,2007,132(7):2557-2576.
[3] Sheng Z, Wang X, Xu G, et al. Analyses of a panel of transcripts identified from a small sample size and construction of RNA networks in hepatocellular carcinoma. Front Genet,2019,8(10):431.
[4] Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res, 2020, 39(1):126.
[5] Chang DZ, Ma Y, Ji B, et al. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol, 2012, 5:15.
[6] Moura IM, Delgado ML, Silva PM, et al. High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med, 2014,43(3):225-231.
[7] Wang L, Zhang J, Wan L, et al. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther, 2015,151:141-151.
[8] Zhuang L, Yang Z, Meng Z. Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in tumor tissues predicted worse overall survival and disease-free survival in hepatocellular carcinoma patients. Biomed Res Int,2018,30:7897346.
[9] Cui Y, Cheng X, Zhang C, et al. Degradation of the human mitotic checkpoint kinase Mps1 is cell cycle-regulated by APC-cCDC20 and APC-cCDH1 ubiquitin ligases. J Biol Chem,2010,285(43):32988-32998.
[10] Li J, Gao JZ, Du JL, et al. Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int J Oncol, 2014,45(4):1547-1555.
[11] Morse MA, Sun W, Kim R,et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res, 2019,25(3):912-920.
[12] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017,11(4):317-370.
[13] Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology, 2015,149(5):1226-1239.
[14] Siegel RL, Miller KD, Jemal A. Cancerstatistics, 2017. CA Cancer J Clin, 2017, 67(1):7-30.
[15] Yang WX, Pan YY, You CG. CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 may be potential therapeutic targets for hepatocellular carcinoma using integrated bioinformatic analysis. Biomed Res Int, 2019,13:1245072.
[16] Chu Z, Zhang X, Li Q, et al. CDC20 contributes to the development of human cutaneous squamous cell carcinoma through the wnt/βcatenin signaling pathway.Int J Oncol, 2019,54(5):1534-1544.
[17] Moura IM, Delgado ML, Silva PM, et al. High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med, 2014,43(3):225-231.
[18] Wu WJ, Hu KS, Wang DS, et al. CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. J Transl Med,2013,11:142.
[19] Chi JJ, Li H, Zhou Z, et al. A novel strategy to block mitotic progression for targeted therapy. EBioMedicine, 2019,49:40-54.
[20] Wang Z, Wan L, Zhong J, et al. CDC20: a potential novel therapeutic target for cancer treatment. Curr Pharm Des,2013,19(18):3210-3214.

HCC组织CDC20表达及其与发病机制的关系研究^*

Pathogenesis of hepatocellular carcinoma associated with CDC20 expression

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高祥瑞, 刘红岩, 张淮, 葛尚. 高场磁共振多b值弥散加权成像鉴别诊断肝血管瘤与肝细胞癌价值探讨^*[J]. 实用肝脏病杂志, 2023, 26(1): 104-107.
[2]	贺潇瑾, 李丹, 周青, 欧阳静, 田玉球, 谭英征. L02细胞乙型肝炎病毒X蛋白和SOCS-1基因水平研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 772-775.
[3]	沈亦亮, 沈冬元, 陈永莹, 江凯, 朱逸明, 葛尚. 肝硬化患者肝内LR-3类结节恶变风险评估及预测模型的建立^*[J]. 实用肝脏病杂志, 2022, 25(6): 836-839.
[4]	张耀辉, 郑章增, 高星, 张亚利. 超声造影时间-强度曲线诊断肝硬化患者肝内小结节病灶价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 861-864.
[5]	石青春, 潘立民, 布凡, 王永强, 关睿骞. 基于TCGA研究细胞坏死相关基因对肝细胞癌患者预后的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 869-872.
[6]	郑希彦, 杜飞, 林志群, 李瑞曦, 周正, 张广权, 周红, 何方平, 史宪杰. 肝细胞癌进展:代谢综合征相关危险因素研究[J]. 实用肝脏病杂志, 2022, 25(6): 877-880.
[7]	高正兴, 李广欣, 宋春青. 癌组织M6A甲基转移酶样蛋白3水平对手术切除后接受索拉非尼治疗的肝细胞癌患者预后的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 885-888.
[8]	吴桐, 张巧丽, 齐雪维. 肝细胞癌RNA结合蛋白功能和预后价值系统分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 693-697.
[9]	杜联江, 李京涛, 崔杰. 肝细胞癌癌组织caspase-3和DcR3蛋白及SNHG12 mRNA水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 706-709.
[10]	李清汉, 甄作均, 何尹韬. 肝动脉化疗栓塞联合射频消融和免疫靶向治疗术后复发的肝细胞癌患者近远期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 714-717.
[11]	施莹, 柏根基, 孙阳. 多模态MRI对肝硬化增生性结节与小肝癌的鉴别诊断价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 722-725.
[12]	布凡, 柴剑波, 白冰, 王万宇, 赵永厚. 基于网络铁死亡相关的长非编码RNA预测肝细胞癌患者预后研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 558-562.
[13]	王晶, 张洁, 赵静. 超声造影联合声触诊组织量化技术鉴别肝血管瘤与肝细胞癌价值研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 575-578.
[14]	金盼盼, 张岭漪. PIVKA-II:一种新型乙型肝炎相关肝癌诊断标记物研究进展[J]. 实用肝脏病杂志, 2022, 25(4): 605-608.
[15]	杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查^*[J]. 实用肝脏病杂志, 2022, 25(2): 153-156.